1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

Summary

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.

Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.

Scope

The different segments of patients with MM are based on their eligibility for an SCT
- What combination therapies are used for various segments?
- What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?
There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.
- What are the dominant mechanisms of action across marketed products?
- Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
- Which product is used more in each country?
- Will there be any label expansions of existing market leaders in any of the countries?
Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.
- What are the various epidemiology trends in each country?
- What factors contribute to the overall epidemiology?
The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.
- What are the various pipeline products based on molecule type, mechanism of action and stage of development?
- Which class is most prominent within the pipeline?
- Do the pipeline molecules offer an advantage over commercially proven mechanisms?
- What are the late-pipeline products expected to be launched in each country in the near future?
Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- What are the current promising pipeline drugs and their efficacy data?
Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.
- Which markets make the most significant contribution to the current market size?
- What are the incidence, diagnosis and treatment trends in these markets?
- What are the factors responsible for difference in the treatment patterns within the four markets?
- Which factors will influence growth rates?
- Will new market entrants lead to substantial changes in annual therapy costs?
Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
- Will the patent expiration be offset by the approval of new therapies?

Reasons to buy

This report will enable you to -
- Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.
- Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.

Table Of Contents

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Etiology 10
2.3 Pathophysiology 11
2.4 Symptoms 12
2.5 Diagnosis and Classification 12
2.6 Epidemiology 15
2.7 Prognosis and Disease Staging 16
2.8 Treatment Options 18
2.8.1 Treatment Algorithm 20
2.8.2 Initial Therapy for Newly Diagnosed Symptomatic Disease 20
2.8.3 Maintenance Therapy 25
2.8.4 Therapy for Relapsed or Refractory Myeloma 26
3 Marketed Products 31
3.1 Overview 31
3.2 Immunomodulatory Agents 31
3.2.1 Thalomid (thalidomide) - Celgene 31
3.2.2 Revlimid (lenalidomide) - Celgene 32
3.2.3 Pomalyst (pomalidomide) - Celgene 32
3.3 Proteasome Inhibitors 33
3.3.1 Velcade (bortezomib) - Millennium Pharmaceuticals/Takeda 33
3.3.2 Kyprolis (carfilzomib) - Onyx 33
3.4 Histone Deacetylase Inhibitors 34
3.4.1 Farydak (panobinostat) - Novartis 34
3.5 Chemotherapy 35
3.5.1 Doxil (doxorubicin HCl liposome injection) - Janssen 35
3.6 Comparative Efficacy and Safety of Marketed Products 35
4 Pipeline Products 38
4.1 Overall Pipeline 38
4.2 Pipeline Analysis by Molecular Target 39
5 Clinical Trials 43
5.1 Failure Rate 43
5.2 Patient Enrolment and Clinical Trial Size 45
5.3 Duration 51
5.4 Competitive Clinical Trials Metrics Analysis 54
5.5 Promising Drug Candidates in the Pipeline 55
5.5.1 Daratumumab - Johnson and Johnson 55
5.5.2 Elotuzumab - AbbVie and Bristol Myers Squibb 56
5.5.3 Ixazomib - Millennium Pharmaceuticals 57
5.5.4 Zolinza (vorinostat) - Merck 59
5.5.5 ARRY-520 (filanesib) - Array Biopharma 60
5.5.6 Aplidin (plitidepsin) - PharmaMar 60
5.6 Heat Map for Pipeline Products 62
6 Market Forecast to 2021 64
6.1 Geographical Markets 64
6.2 Asia-Pacific Market 65
6.3 India 66
6.3.1 Treatment Usage Patterns 66
6.3.2 Annual Cost of Therapy 67
6.3.3 Market Size 67
6.4 China 68
6.4.1 Treatment Usage Patterns 68
6.4.2 Annual Cost of Therapy 68
6.4.3 Market Size 69
6.5 Australia 70
6.5.1 Treatment Usage Patterns 70
6.5.2 Annual Cost of Therapy 71
6.5.3 Market Size 71
6.6 Japan 73
6.6.1 Treatment Usage Patterns 73
6.6.2 Annual Cost of Therapy 74
6.6.3 Market Size 75
7 Drivers and Barriers for the Disease Market 76
7.1 Drivers 76
7.1.1 Rising Prevalence 76
7.1.2 Increasing Therapeutic Options 76
7.1.3 Limited Generic Competition 76
7.2 Barriers 76
7.2.1 Limited Target Patient Population 76
7.2.2 Large Undiagnosed Pool 76
7.2.3 Lower Usage of Costlier Therapies in India and China 77
7.2.4 Costly Drug Development 77
8 Deals and Strategic Consolidations 78
8.1 Licensing Deals 78
8.1.1 PharmaMar Announces Licensing Agreement with TTY Biopharm for Aplidin in Hematological Cancers 84
8.1.2 Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 84
8.1.3 Genentech Enters into Licensing Agreement with Seattle Genetics - Now Terminated 85
8.1.4 OncoPep Enters into Licensing Agreement with Dana-Farber Cancer Institute for Cancer Vaccine Technology 85
8.1.5 PharmaMar Enters into Licensing Agreement with Chugai for Aplidin 85
8.1.6 Onyx Enters into Licensing Agreement with Ono Pharma for Kyprolis and Oprozomib 85
8.2 Co-development Deals 86
8.2.1 Celgene Enters into Co-development Agreement with MedImmune 90
8.2.2 Acetylon Enters into Co-development Agreement with Leukemia and Lymphoma Society 90
8.2.3 Boehringer Ingelheim Enters into Collaboration Agreement with Micromet 91
8.2.4 Multiple Myeloma Research Foundation Enters into Co-development Agreement with Onyx 91
8.2.5 Dana-Farber Cancer Institute Enters into Agreement with MannKind 91
8.2.6 Nordic Nanovector Enters into Co-development Agreement with Affibody 91
9 Appendix 92
9.1 All Pipeline Drugs by Phase of Development 92
9.1.1 Discovery 92
9.1.2 Preclinical 94
9.1.3 Investigational New Drug/Clinical Trial Application-Filed 97
9.1.4 Phase I 97
9.1.5 Phase II 101
9.1.6 Phase III 104
9.1.7 Pre-registration 104
9.2 Market Forecasts to 2021 105
9.2.1 Asia-Pacific 105
9.2.2 India 105
9.2.3 China 106
9.2.4 Australia 106
9.2.5 Japan 107
9.3 Bibliography 107
9.4 Research Methodology 113
9.4.1 Secondary Research 113
9.4.2 Marketed Product Profiles 114
9.4.3 Late-Stage Pipeline Candidates 114
9.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 114
9.4.5 Forecasting Model 115
9.4.6 Deals Data Analysis 116
9.5 Expert Panel Validation 116
9.6 Contact Us 117
9.7 Disclaimer 117

1.1 List of Tables
Table 1: Multiple Myeloma Therapeutics Market, Initial Screening in Suspected Myeloma Patients 13
Table 2: Multiple Myeloma Therapeutics Market, Diagnostic Criteria for MGUS, Asymptomatic Myeloma and Symptomatic Myeloma 14
Table 3: Multiple Myeloma Therapeutics Market, Myeloma-Related Organ or Tissue Impairment 14
Table 4: Multiple Myeloma Therapeutics Market, Disease Staging, Durie-Salmon Staging System 16
Table 5: Multiple Myeloma Therapeutics Market, Prognostic Factors 17
Table 6: Multiple Myeloma Therapeutics Market, Prognostic Factors 19
Table 7: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Discovery, 2015 92
Table 8: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Preclinical, 2015 94
Table 9: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015 97
Table 10: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase I, 2015 97
Table 11: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase II, 2015 101
Table 12: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase III, 2015 104
Table 13: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015 104
Table 14: Multiple Myeloma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021 105
Table 15: Multiple Myeloma Therapeutics Market, India, Market Forecast, 2014-2021 105
Table 16: Multiple Myeloma Therapeutics Market, China, Market Forecast, 2014-2021 106
Table 17: Multiple Myeloma Therapeutics Market, Australia, Market Forecast, 2014-2021 106
Table 18: Multiple Myeloma Therapeutics Market, Japan, Market Forecast, 2014-2021 107

1.2 List of Figures
Figure 1: Multiple Myeloma Therapeutics Market, Australia, Age-Specific Incidence Rate and Average Number of Cases, 2007-2011 15
Figure 2: Multiple Myeloma Therapeutics Market, Treatment Algorithm for Myeloma 20
Figure 3: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Efficacy 36
Figure 4: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Safety 36
Figure 5: Multiple Myeloma Therapeutics Market, Global, Heat Map for Maintenance Treatment 37
Figure 6: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Efficacy 37
Figure 7: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Safety 37
Figure 8: Multiple Myeloma Therapeutics Market, Global, Overview of Pipeline Products 39
Figure 9: Multiple Myeloma Therapeutics Market, Global, Target Families in Pipeline 42
Figure 10: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase (%), 2006-2015 43
Figure 11: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type (%), 2006-2015 44
Figure 12: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target (%), 2006-2015 45
Figure 13: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2015 46
Figure 14: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2015 47
Figure 15: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2015 49
Figure 16: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2015 50
Figure 17: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2015 52
Figure 18: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2015 53
Figure 19: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 54
Figure 20: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 55
Figure 21: Multiple Myeloma Therapeutics Market, Global, Pipeline Heat Map, 2015 62
Figure 22: Multiple Myeloma Therapeutics Market, Asia-Pacific, Treatment Patterns (‘000) and Market Size ($bn), 2014-2021 65
Figure 23: Multiple Myeloma Therapeutics Market, India, Treatment Patterns (‘000), 2014-2021 66
Figure 24: Multiple Myeloma Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021 67
Figure 25: Multiple Myeloma Therapeutics Market, India, Market Size ($m), 2014-2021 67
Figure 26: Multiple Myeloma Therapeutics Market, China, Treatment Patterns (‘000), 2014-2021 68
Figure 27: Multiple Myeloma Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021 69
Figure 28: Multiple Myeloma Therapeutics Market, China, Market Size ($m), 2014-2021 70
Figure 29: Multiple Myeloma Market, Australia, Treatment Usage Patterns (‘000), 2014-2021 70
Figure 30: Multiple Myeloma Market, Australia, Annual Cost of Therapy ($), 2014-2021 71
Figure 31: Multiple Myeloma Therapeutics Market, Australia, Market Size ($m), 2014-2021 71
Figure 32: Multiple Myeloma Market, Japan, Treatment Usage Patterns (‘000), 2014-2021 73
Figure 33: Multiple Myeloma Market, Japan, Annual Cost of Therapy ($), 2014-2021 74
Figure 34: Multiple Myeloma Therapeutics Market, Japan, Market Size ($m), 2014-2021 75
Figure 35: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015 78
Figure 36: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006-2015 79
Figure 37: Multiple Myeloma Therapeutics Market, Global, Number of Deals and Aggregate Deal Value ($m), 2006-2015 80
Figure 38: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015 81
Figure 39: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015 82
Figure 40: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2015 84
Figure 41: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Region, 2006-2015 86
Figure 42: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, 2006-2015 87
Figure 43: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2015 88
Figure 44: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2015 89
Figure 45: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015 90

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.